Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 18/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PKLR | P30613 | 1/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.45 |
| ▸ | RORA | P35398 | 1/20 | 0.45 |
| ▸ | RORB | Q92753 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24286258 | 0.90 | PKM (0.47) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286236 | 0.88 | PKM (0.52) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286729 | 0.87 | PKM (0.48) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286389 | 0.86 | PKM (0.50) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24287340 | 0.85 | PKM (0.46) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286519 | 0.85 | PKM (0.49) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286425 | 0.85 | PKM (0.49) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286242 | 0.84 | RORC (0.66) | RORCPKMPKLRNR1I2RORA | |
| SCHEMBL24286274 | 0.83 | PKM (0.47) | RORCPKMPKLRCYP11B1CYP11B2 | |
| SCHEMBL24286390 | 0.81 | PKM (0.57) | RORCPKMPKLRCYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3307738-B1 | ARYL DIHYDRO-2H-BENZO[B][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORY AND THE TREATMENT OF DISEASE | UNIV MICHIGAN REGENTS (US) | 2022-04-20 | — | — | EP | disclosed |